FACS assay shows that recombinant Human OX40 Ligand, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. OXL-H5250) can bind to 293T cell overexpressing human OX40. The concentration of OX40 Ligand is 0.003 μg/ml (Routinely tested).
FACS analysis shows that the binding of Human OX40 Ligand, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. OXL-H5250) to 293T overexpressing OX40 was inhibited by increasing concentration of neutralizing anti-OX40 antibody. The concentration of OX40 Ligand used is 0.002 μg/ml. IC50=3.021 μg/ml (Routinely tested).
Loaded Human OX40 Ligand, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. OXL-H5250) on Protein A Biosensor, can bind Human OX40, His Tag (Cat. No. OX0-H5224) with an affinity constant of 2 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Oncolytic virus cancer therapeutics (DNAtrix) | MYX-135; DNX-2440; DNX-2450 | Phase 1 Clinical | Dnatrix Inc | Liver Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Pancreatic Neoplasms; Colonic Neoplasms; Neoplasms; Sarcoma; Breast Neoplasms; Gastrointestinal Stromal Tumors; Colorectal Neoplasms; Carcinoma, Squamous Cell; Melanoma | Details |
| SAR-443726 | SAR-443726 | Phase 1 Clinical | Sanofi | Dermatitis, Atopic | Details |
| anti-cancer mRNA therapeutics (Moderna Therapeutics) | mRNA-2752 | Phase 1 Clinical | Astrazeneca Plc | Solid tumours; Lymphoma | Details |
| RP-3 | RP-3 | Phase 1 Clinical | Replimune Inc | Solid tumours | Details |
| mRNA-2416 | mRNA-2416; OX40L mRNA - Moderna Therpeutics | Phase 2 Clinical | Moderna Inc | Ovarian Neoplasms; Solid tumours; Lymphoma | Details |
| Amlitelimab | KY-1005; SAR-445229 | Phase 2 Clinical | Kymab, Sanofi | Autoimmune Diseases; Immune System Diseases; Dermatitis, Atopic; Eczema | Details |
This web search service is supported by Google Inc.
A-Z
